Topic is suspended
Status Suspended
Decision Selected
Process STA 2018
ID number 1381


Key events during the development of the guidance:

Date Update
23 October 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of neratinib for treating HER2-positive breast cancer after 2 therapies. Following on from advice from the company, they are currently not in a position to submit all evidence to NICE whilst they consider their regulatory filing strategy, therefore the appraisal has been suspended. NICE will continue to monitor the situation and provide an update if and when the situation changes.
23 October 2020 Suspended. Topic is suspended
22 June 2020 Please note that following on from advice received from the company this appraisal has now been scheduled into the work programme We anticipate that the appraisal will begin during early February 2021 when we will write to you about how you can get involved.
30 September 2019 Please note that following on from advice received from the company, the timelines for this appraisal remain to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
27 September 2019 In progress. Referred 13/02/2018

For further information on our processes and methods, please see our CHTE processes and methods manual